Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Actinogen Medical

News headline image
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
News headline image
Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
From Actinogen Medical
Via GlobeNewswire
Tickers ASX:ACW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.